Inhibikase Therapeutics (IKT) Current Assets (2020 - 2026)

Inhibikase Therapeutics (IKT) has reported Current Assets for 7 consecutive years, with $172.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Current Assets rose 82.85% year-over-year to $172.2 million; the TTM figure through Mar 2026 stood at $172.2 million (up 82.85% YoY), while the FY2025 annual figure was $180.1 million, up 82.94% from the prior year.
• Current Assets fell to $172.2 million in Q1 2026 per IKT's latest filing, from $180.1 million in the prior quarter.
• Across five years, Current Assets topped out at $180.1 million in Q4 2025 and bottomed at $4.2 million in Q3 2024.
• Historically, Current Assets has averaged $56.5 million across 5 years, with a median of $27.8 million in 2022.
• Annual changes were most pronounced in 2024 — Current Assets slumped 76.13% — and 2025, when it soared 1774.34%.
• Inhibikase Therapeutics' Current Assets stood at $24.4 million in 2022, then tumbled by 41.69% to $14.2 million in 2023, then soared by 592.78% to $98.5 million in 2024, then jumped by 82.94% to $180.1 million in 2025, then fell by 4.4% to $172.2 million in 2026.
• Business Quant data shows IKT's Current Assets at $172.2 million in Q1 2026, $180.1 million in Q4 2025, and $78.5 million in Q3 2025.